
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare is supported by unmatched scale as the largest integrated acute-care provider in the U.S., with 190 hospitals and more than 2,500 outpatient facilities across 19 states and the U.K., which strengthens its competitive moat and market access. Its 3Q26 core adjusted EBITDA growth of about 10%, expected FY26 EBITDA of $15.90B, and favorable managed care pricing reflect resilient demand, strong rate positioning, and disciplined cost control despite Medicaid supplemental payment headwinds. Robust free cash flow, roughly $4.5B of operating cash flow, and ample balance-sheet capacity for buybacks, capex, and M&A further reinforce a positive long-term fundamental outlook.
Bears say
HCA Healthcare is facing a fundamentally negative setup because its earnings are exposed to worsening payor mix, with HIX-to-uninsured migration and the expiration of enhanced subsidies pressuring reimbursement while government and managed-care rates lag inflation. Competitive intensity, tighter clinical labor supply, and higher staffing, professional fee, and supply costs threaten margins and cash flow, even as management already flagged FY26 HIX headwinds at or above the $1.2 billion high end of guidance. The result is a business that may still show solid volumes, but with elective surgery weakness, regulatory uncertainty, and limited margin protection that can offset operational growth.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About HCA Healthcare (HCA) Forecast
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares